These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 27301486

  • 21. Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Finn MB, Penfound TA, Salehi S, Ogega CO, Dold C, Plante O, Dale JB.
    Vaccine; 2024 Sep 17; 42(22):126205. PubMed ID: 39141987
    [Abstract] [Full Text] [Related]

  • 22. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
    Dale JB, Smeesters PR, Courtney HS, Penfound TA, Hohn CM, Smith JC, Baudry JY.
    Vaccine; 2017 Jan 03; 35(1):19-26. PubMed ID: 27890396
    [Abstract] [Full Text] [Related]

  • 23. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
    Nordström T, Pandey M, Calcutt A, Powell J, Phillips ZN, Yeung G, Giddam AK, Shi Y, Haselhorst T, von Itzstein M, Batzloff MR, Good MF.
    J Immunol; 2017 Oct 15; 199(8):2794-2802. PubMed ID: 28904125
    [Abstract] [Full Text] [Related]

  • 24. Immune response to superoxide dismutase in group A streptococcal infection.
    McMillan DJ, Davies MR, Good MF, Sriprakash KS.
    FEMS Immunol Med Microbiol; 2004 Apr 09; 40(3):249-56. PubMed ID: 15039102
    [Abstract] [Full Text] [Related]

  • 25. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
    Guerino MT, Postol E, Demarchi LM, Martins CO, Mundel LR, Kalil J, Guilherme L.
    Vaccine; 2011 Oct 26; 29(46):8250-6. PubMed ID: 21907752
    [Abstract] [Full Text] [Related]

  • 26. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
    Ozberk V, Pandey M, Good MF.
    Hum Vaccin Immunother; 2018 Oct 26; 14(8):2034-2052. PubMed ID: 29873591
    [Abstract] [Full Text] [Related]

  • 27. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W, Hayman W, Russell-Jones G, Good M.
    Adv Exp Med Biol; 1997 Oct 26; 418():859-61. PubMed ID: 9331788
    [No Abstract] [Full Text] [Related]

  • 28. Molecular biology of Group A Streptococcus and its implications in vaccine strategies.
    Brahmadathan NK.
    Indian J Med Microbiol; 2017 Oct 26; 35(2):176-183. PubMed ID: 28681803
    [Abstract] [Full Text] [Related]

  • 29. The quest for GAS vaccine.
    Pandey M, Good MF.
    Oncotarget; 2015 Oct 27; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin.
    Sheoran AS, Artiushin S, Timoney JF.
    Vaccine; 2002 Feb 22; 20(11-12):1653-9. PubMed ID: 11858875
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
    Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S.
    Vaccine; 2005 Sep 23; 23(40):4852-9. PubMed ID: 15990202
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, Toth I.
    J Med Chem; 2012 Oct 11; 55(19):8515-23. PubMed ID: 22974133
    [Abstract] [Full Text] [Related]

  • 36. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R, Kasper DL.
    Clin Infect Dis; 2007 Oct 01; 45(7):863-5. PubMed ID: 17806050
    [No Abstract] [Full Text] [Related]

  • 37. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
    Wozniak A, García P, Geoffroy EA, Aguirre DB, González SA, Sarno VA, Dale JB, Salazar-Echegarai FJ, Vera A, Bueno SM, Kalergis AM.
    Clin Vaccine Immunol; 2014 Sep 01; 21(9):1343-9. PubMed ID: 25056362
    [Abstract] [Full Text] [Related]

  • 38. A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein.
    Lin HX, Huang DY, Wang Y, Lu CP, Fan HJ.
    Vaccine; 2011 Sep 16; 29(40):7027-34. PubMed ID: 21807055
    [Abstract] [Full Text] [Related]

  • 39. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
    Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS.
    Vaccine; 2009 Nov 12; 27(48):6799-806. PubMed ID: 19729086
    [Abstract] [Full Text] [Related]

  • 40. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.
    J Immunol; 2016 Apr 15; 196(8):3364-74. PubMed ID: 26969753
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.